European Journal of Neurology

Papers
(The H4-Index of European Journal of Neurology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
139
95
Clinical and Genetic Reassessment in Patients With Clinically Diagnosed Hereditary Polyneuropathy95
The 2022 European postgraduate (residency) programme in neurology in a historical and international perspective93
Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study87
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study85
Concerns Regarding “Small Fiber Morphology and Function in Inclusion Body Myositis—A Multimodal Assessment Including Confocal Corneal Microscopy”74
Issue Information70
Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy69
Central nervous system crystal‐storing histiocytosis: A case report and literature review68
ePoster66
Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis66
Lessons from the past to understand the future62
CCR5‐Δ32polymorphism—a possible protective factor from gait impairment amongst post‐stroke patients60
Ischaemic cerebral small vessel disease caused by adenosine deaminase 2 deficiency syndrome59
Hearing impairment and development of parkinsonism and possible rapid eye movement sleep behaviour disorder: A CLSA prospective population‐based study53
Basal ganglia ischaemic infarction after thrombectomy: cognitive impairment at acute stage53
Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift51
Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis50
Cost‐effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health‐related quality of life50
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease49
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study48
Electroencephalography functional connectivity—A biomarker for painful polyneuropathy47
Neurovascular Involvement in Fibromuscular Dysplasia: A Clue for Reappraisal of Old Classifications47
Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report46
The effect of influenza vaccination on the rate of dementia amongst older adults44
Prioritization process for European Academy of Neurology clinical practice guidelines43
Comparative features and outcomes of major neurological complications of COVID‐1943
The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications42
Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients42
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP) antibodies or vice versa in non‐responders: A controlled cohort study42
Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms42
Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage41
Correlation between patient‐reported manual ability and three objective measures of upper limb function in people with multiple sclerosis41
Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study40
Out‐of‐hospital versus in‐hospital status epilepticus: The role of etiology and comorbidities39
Risk factors, neuroimaging correlates and prognosis of the motoric cognitive risk syndrome: A population‐based comparison with mild cognitive impairment39
Neuropathy in GAA‐FGF14 Late‐Onset Cerebellar Ataxia (SCA27B): Prevalence and Characteristics39
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment39
0.056084156036377